Research Pilot Project Program Abstract: The overall goal of the Research Pilot Project Program in the Phase 111 funding cycle is to promote interdisciplinary research in the broad area of cellular signaling, encompassing projects in cell-cell communication, endocytosis and trafficking, biology and therapy of oral cancer, and cancer biology and immunology. Our ongoing research pilot project program, for both individual and collaborative projects, has been extremely successful. Having awarded $827,400 during the first nine years of funding, our program has led to development of multiple external awards totaling over $9.88 million received from NIH and the American Cancer Society. Thus, pilot project funding through the NCCS provides a clear return of over $11 for every dollar invested, without even taking into consideration additional grants arising from the first external funding that benefitted from the pilot funding. Past NCCS pilot projects have either been awarded to single investigators or to collaborating co-investigators. We propose to make a total of $2 million available by awarding four, one-year collaborative pilot grants ($100K) and 16, two-year pilot project grants ($50K per year) during Phase III. The Dean of the UNMC College of Dentistry (COD), the Director of the Eppley Institute (El), and the UNMC Vice Chancellor for Research (VCR) have committed a combined total of $150K per year to supplement NIH funds for NCCS pilot grants during Phase 111. Thus, over the five-year span of Phase III, $1,250K in NIH funds provided by the NCCS will be partnered with $250K each from the COD, Eppley, and the VCR ($750K of combined institutional support, or a 60% match) for this crucial component of the NCCS. Moreover, the Director of the Eppley Institute has pledged a further $50,000 per year for the five years beyond Phase 111, bringing the UNMC commitment to $1 million overall. A rigorous review process for such applications involving review and prioritization of proposals by the NCCS Executive Committee and then critique by the External Advisory Council is already in place to ensure that the projects funded through this mechanism are the most meritorious and have the highest probability of generating the key data needed to compete successfully for external funding. The mechanisms for issuing requests for applications, the proposal review process, notification of awards, evaluation and monitoring of progress on the pilot projects, and follow-up on applications to external funding agencies are described herein.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-TWD-C)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
United States
Zip Code
Awasthee, Nikee; Rai, Vipin; Chava, Srinivas et al. (2018) Targeting I?appaB kinases for cancer therapy. Semin Cancer Biol :
Luan, Haitao; Mohapatra, Bhopal; Bielecki, Timothy A et al. (2018) Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer Res 78:2524-2535
Xie, Shuwei; Reinecke, James B; Farmer, Trey et al. (2018) Vesicular trafficking plays a role in centriole disengagement and duplication. Mol Biol Cell 29:2622-2631
Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276
Qi, Dianjun; Wu, Shaohua; Lin, Haishuang et al. (2018) Establishment of a Human iPSC- and Nanofiber-Based Microphysiological Blood-Brain Barrier System. ACS Appl Mater Interfaces 10:21825-21835
Tian, Tian; Bi, Chengfeng; Hein, Ashley L et al. (2018) Rac1 is a novel therapeutic target in mantle cell lymphoma. Blood Cancer J 8:17
Huang, Yunlong; Li, Yuju; Zhang, Hainan et al. (2018) Zika virus propagation and release in human fetal astrocytes can be suppressed by neutral sphingomyelinase-2 inhibitor GW4869. Cell Discov 4:19
Fan, Wei; Zhang, Wenting; Alshehri, Sameer et al. (2018) Increasing time on target: utilization of inhibitors of cysteine cathepsins to enhance the tumor retention of receptor-targeted agents. Chem Commun (Camb) 54:11268-11271
Ouellette, Scot P; Messerli, Parker R; Wood, Nicholas A et al. (2018) Characterization of Chlamydial Rho and the Role of Rho-Mediated Transcriptional Polarity during Interferon Gamma-Mediated Tryptophan Limitation. Infect Immun 86:
Nallasamy, Palanisamy; Chava, Srinivas; Verma, Sumit S et al. (2018) PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. Semin Cancer Biol 52:53-65

Showing the most recent 10 out of 159 publications